2011
DOI: 10.1200/jco.2011.29.15_suppl.6116
|View full text |Cite
|
Sign up to set email alerts
|

The 2010 National Comprehensive Cancer Network (NCCN) research benchmarking survey (RBS): Clinical trials in the academic cancer center.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2012
2012
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 0 publications
0
5
0
Order By: Relevance
“…Finally, the 2008 NCCN® benchmark study examined data from 17 participating NCCN member institutions and cited a range of 10–24% total accrual for all ages and diagnoses [15]. The 2010 follow-up to this study cited a 15.1% rate of accrual over a 12-month time period for 20 participating institutions [16]. These studies only examined therapeutic trials.…”
Section: Discussionmentioning
confidence: 99%
“…Finally, the 2008 NCCN® benchmark study examined data from 17 participating NCCN member institutions and cited a range of 10–24% total accrual for all ages and diagnoses [15]. The 2010 follow-up to this study cited a 15.1% rate of accrual over a 12-month time period for 20 participating institutions [16]. These studies only examined therapeutic trials.…”
Section: Discussionmentioning
confidence: 99%
“…The proportion of patients receiving first-line therapy in a clinical trial was similar to the 15% accrual rate reported among all patients treated at NCCN Member Institutions. 8 A 2-drug chemotherapy regimen is the current standard of care for first-line treatment of NSCLC. In select subgroups, targeted agents may be used either in place of or in combination with a chemotherapy doublet.…”
Section: Main Findingsmentioning
confidence: 99%
“…The National Cancer Institute and the National Comprehensive Cancer Network have made enrolling patients in cancer clinical trials a priority, validating that the best management of any patient with cancer is on a clinical trial . The centrality of clinical trials to cancer therapy is reinforced by the large number of emerging biomarker therapies being tested, with resulting improvements in patient outcomes .…”
Section: Introductionmentioning
confidence: 99%